Could psychedelics become a new generation of treatments for depression and other psychiatric disorders? This question is no longer confined to basic research. Several therapies based on classical psychedelics have advanced into late-stage clinical development and have reported encouraging results. DT120, an LSD-based candidate, and COMP360, a synthetic psilocybin formulation, have both received breakthrough therapy designation from the U.S. Food and Drug Administration.